Table 2.

Univariate analysis of potential predictors of response to dose intensification

	Week 24 responders n (%), median (range)	Week 24 non-responders n (%), median (range)	P value
n	10	10
Gender (male vs female)	7 vs 3 (70 vs 30)	7 vs 3 (70 vs 30)	>0.99
IBD phenotype (UC vs CD)	7 vs 3 (70 vs 30)	8 vs 2 (80 vs 20)	>0.99
Age, years	40 (18–69)	44 (24–63)	0.73
Concomitant immunomodulator (combotherapy vs monotherapy)	4 vs 6 (40 vs 60)	5 vs 5 (50 vs 50)	>0.99
Prior anti-TNF experience (exposed vs naïve)	9 vs 1 (90 vs 10)	8 vs 2 (80 vs 20)	>0.99
Duration on vedolizumab prior to dose intensification, months	7 (3–23)	7 (3–16)	0.87
CRP at baseline, mg/L	5 (1–21)	13 (1–23)	0.045
Week 12 response (response vs non-response)	7 vs 3 (70 vs 30)	1 vs 9 (10 vs 90)	0.020

CD, Crohn’s disease; CRP, C reactive protein; IBD, inflammatory bowel disease; TNF, tumour necrosis factor; UC, ulcerative colitis.